This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Cipaglucosidase alfa
DrugBank Accession Number
DB16708
Background

Cipaglucosidase alfa is under investigation in clinical trial NCT03911505 (ZIP Study - a Study of the Safety, Pharmacokinetics, Efficacy, Pharmacodynamics, and Immunogenicity of ATB200/AT2221 in Pediatric Subjects Aged 0 to < 18 Years With Pompe Disease).

Type
Biotech
Groups
Investigational
Synonyms
  • Cipaglucosidase alfa
  • Recombinant human acid alpha-glucosidase optimized for high expression of mannose 6-phosphate
External IDs
  • AT GAA
  • ATB-200
  • ATB200
  • WHO 11346

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
4SED7F4BSG
CAS number
2359727-71-0

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingTreatmentLate-onset Pompe Disease1
3CompletedTreatmentLate-onset Pompe Disease1
3RecruitingTreatmentGlycogen Storage Disease Type II Infantile Onset1
3RecruitingTreatmentLate-onset Pompe Disease1
1, 2Active Not RecruitingTreatmentPompe's Disease1
Not AvailableAvailableNot AvailablePompe Disease (Infantile-Onset)1
Not AvailableAvailableNot AvailablePompe's Disease1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at July 19, 2021 21:26 / Updated at July 22, 2021 04:38